Drug Profile

Exenatide once-monthly suspension - Amylin

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amylin Pharmaceuticals
Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
Mechanism of Action Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Type 2 diabetes mellitus

Most Recent Events

08 Aug 2012 Amylin Pharmaceuticals has been acquired by Bristol-Myers Squibb
08 Nov 2011 Exenatide suspension is no longer licensed to Eli Lilly worldwide
25 Jun 2011 Efficacy and adverse events data from a phase II trial in Type 2 diabetes mellitus presented at the 71^st Scientific Sessions of the American Diabetes Association (ADA-2011)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com